Peptide reference

Sermorelin

A growth-hormone-releasing hormone analog used to stimulate the body's own GH production.

Evidence: Clinical experience + limited trialsCategory 2 — awaiting reclassification

Last clinically reviewed: May 2026 by Dr. Lena Park, MD

What it is and what it does

What the evidence supports

Sermorelin is a synthetic analog of GHRH (1–29) that stimulates the anterior pituitary to release endogenous growth hormone in a pulsatile, physiologic pattern. It has a long history of clinical use in pediatric growth hormone deficiency, where randomized trials demonstrated reliable increases in IGF-1 and linear growth.

What the evidence is less clear on

In healthy adults, long-term outcome data is limited. Most studies are small, short-duration, and focused on surrogate markers like IGF-1 rather than meaningful endpoints such as body composition, longevity, or recovery. The magnitude and durability of benefit for off-label longevity use remains an open question.

What we tell our patients

Sermorelin is a reasonable choice if your IGF-1 is genuinely low and you understand the data is thinner than the marketing suggests. We don't promise a fountain of youth. We promise honest dosing, real labs, and a physician who will pull you off it if the numbers don't move.

Drug and peptide interactions

Medications that may reduce effectiveness	Medications that require closer monitoring	Peptide stacking notes
Glucocorticoids (prednisone, dexamethasone) blunt GH response. Chronic high-dose opioids suppress the hypothalamic-pituitary axis. Untreated hypothyroidism — correct first or expect minimal response.	Insulin and oral hypoglycemics — GH elevation can affect glucose tolerance. Levothyroxine — recheck TSH at 8 weeks; doses may need adjustment. SSRIs — small studies suggest altered GH pulsatility.	Commonly stacked with ipamorelin for additive GH pulse amplitude. Avoid stacking with exogenous HGH — defeats the physiologic premise. BPC-157 has no known pharmacokinetic interaction.

Before we prescribe anything, we need your complete medication list. Your physician cannot catch an interaction they don't know about.

Side effects — what to expect and when to worry

Normal and expected

Symptom	What it might mean	What to do
Mild injection site redness	Local histamine response, typical of subcutaneous peptides.	Rotate sites. Resolves within 24 hours.
Flushing in the first 30 minutes	Vasodilation from acute GHRH stimulation.	Expected. Diminishes over the first two weeks.
Vivid dreams	GH pulse affecting REM architecture.	Typically self-resolves. Dose at bedtime if disruptive.

Worth mentioning at your next check-in

Symptom	What it might mean	What to do
Persistent water retention	Sodium retention from sustained IGF-1 elevation.	Mention at month-1 check-in. May require dose reduction.
Joint stiffness lasting >2 weeks	Common at higher IGF-1 levels; usually dose-related.	We will review labs and likely reduce dose 20–30%.
New numbness or tingling in hands	Possible early carpal tunnel from fluid shifts.	Contact us within a week; do not wait for the next visit.

Stop and contact your doctor immediately

Symptom	What it might mean	What to do
Sudden severe headache or vision change	Rule out intracranial pressure changes.	Stop immediately. Seek emergency evaluation.
Chest pain or shortness of breath	Possible cardiovascular event; GH affects fluid and cardiac load.	Call 911. Do not resume without cardiology clearance.
Signs of an allergic reaction (hives, swelling, wheezing)	Hypersensitivity to peptide or excipient.	Stop and contact us same-day. Use epinephrine if prescribed.

Who should not use this

Absolute contraindications — we will not prescribe

×Active malignancy or history of cancer within 5 years.
×Active diabetic retinopathy.
×Pregnancy or active attempts to conceive.
×Known hypersensitivity to sermorelin or mannitol.
×Closed epiphyses workup not yet complete in patients under 25.

Relative contraindications — requires careful physician evaluation

~Type 2 diabetes with A1c above 7.5%.
~Untreated obstructive sleep apnea.
~Chronic kidney disease, stage 3 or worse.
~History of pituitary adenoma (requires MRI review).
~Active glucocorticoid therapy above physiologic replacement.

About 1 in 5 people who take our quiz don't qualify. We tell them that directly, explain why, and don't try to upsell them. We'd rather lose a sale than put someone at risk.

Monitoring protocol

Milestone 01
Pre-treatment
Baseline IGF-1, fasting glucose, A1c, CMP, lipid panel, TSH. Cancer screening current per USPSTF.
Milestone 02
Month 1 check-in
Tolerance review, injection technique, side effect screen. No labs unless symptomatic.
Milestone 03
Week 6 labs
Repeat IGF-1 to confirm physiologic response. Fasting glucose. Adjust dose if IGF-1 is above target.
Milestone 04
Quarterly
Full metabolic panel, IGF-1, symptom review, blood pressure trend, and goal reassessment.
Milestone 05
Annually
Comprehensive labs, cancer screening verification, and a frank conversation about whether to continue.

Evidence appendix

Considering Sermorelin? Take our 2-minute eligibility quiz to see if it's appropriate for you.

Start the quiz